Clinical trial registry record

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 17, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06087458
Last registry update
August 17, 2026
Status
Active Not Recruiting
Phase
Phase 1, Phase 2
Sponsor
Perceive Biotherapeutics, Inc.
Enrollment
60
Countries
United States, Australia, Israel
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · SINGLE GROUP · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
60
Population
ALL · 60 Years
Duration
2023-06-21 to 2028-06-01
Intervention
VOY-101
Comparator
Not reported
Outcomes measured
Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101 — 24…; Phase 1: Change from Baseline in markers of inflammation — Baseline to Month 24; Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy. — Month 12; Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic…; Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors — Baseline through 24 M…; Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101. — Baseline through 24 Months; Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity — 24 Months; Phase 1/2: Development of macular neovascularization — Month 24; Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101 — 24 Months; Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy le…; Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity — Baseline through Month 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON